For example, the PDX-IM model of 85 patients with metastatic colorectal cancer was established to predict resistance to targeted anti-EGFR therapies using a combination of anti-HER-2 and anti-EGFR therapies. Here, ERBB2 is linked to metastatic colorectal cancer.